- Home
- TYRA vs MYI Comparison
TYRA vs MYI Comparison
Compare TYRA & MYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- MYI
- Stock Information
- Founded
- TYRA 2018
- MYI 1992
- Country
- TYRA United States
- MYI United States
- Employees
- TYRA N/A
- MYI N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- MYI Investment Bankers/Brokers/Service
- Sector
- TYRA Health Care
- MYI Finance
- Exchange
- TYRA Nasdaq
- MYI Nasdaq
- Market Cap
- TYRA 576.6M
- MYI 697.2M
- IPO Year
- TYRA 2021
- MYI N/A
- Fundamental
- Price
- TYRA $10.47
- MYI $10.49
- Analyst Decision
- TYRA Strong Buy
- MYI
- Analyst Count
- TYRA 7
- MYI 0
- Target Price
- TYRA $30.86
- MYI N/A
- AVG Volume (30 Days)
- TYRA 364.1K
- MYI 256.7K
- Earning Date
- TYRA 08-06-2025
- MYI 01-01-0001
- Dividend Yield
- TYRA N/A
- MYI 4.81%
- EPS Growth
- TYRA N/A
- MYI N/A
- EPS
- TYRA N/A
- MYI N/A
- Revenue
- TYRA N/A
- MYI N/A
- Revenue This Year
- TYRA N/A
- MYI N/A
- Revenue Next Year
- TYRA N/A
- MYI N/A
- P/E Ratio
- TYRA N/A
- MYI N/A
- Revenue Growth
- TYRA N/A
- MYI N/A
- 52 Week Low
- TYRA $6.42
- MYI $9.32
- 52 Week High
- TYRA $29.60
- MYI $11.70
- Technical
- Relative Strength Index (RSI)
- TYRA 58.12
- MYI 49.45
- Support Level
- TYRA $9.93
- MYI $10.37
- Resistance Level
- TYRA $10.49
- MYI $10.63
- Average True Range (ATR)
- TYRA 0.59
- MYI 0.07
- MACD
- TYRA 0.08
- MYI 0.01
- Stochastic Oscillator
- TYRA 94.30
- MYI 42.86
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About MYI Blackrock MuniYield Quality Fund III Inc
BLACKROCK MUNIYIELD QUALITY FUND III, INC. is a investment management company. Its investment objective is to provide shareholders with a high level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in various sectors such as Transportation; Utilities; Health; Education; Tobacco and others.